Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

BCAB

BioAtla Inc

Dec 24 • 04:00PM ET

0.6206

Dollar change +0.0096
Percentage change 1.57	%

Healthcare • Biotechnology • USA • NASD

Peers: ADPT ALXO IDYA IMTX AGEN TCRX SRRK ANVS HOOK

| Held by: VTI VXF IWC FORH DFAT BTEC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.70	Insider Own	19.29%	Shs Outstand	48.35M	Perf Week	-51.91%
Market Cap	36.01M	Forward P/E	-	EPS next Y	-1.41	Insider Trans	0.00%	Shs Float	39.02M	Perf Month	-59.87%
Income	-81.82M	PEG	-	EPS next Q	-0.39	Inst Own	32.74%	Short Float	10.11%	Perf Quarter	-60.99%
Sales	11.00M	P/S	3.27	EPS this Y	40.93%	Inst Trans	-22.26%	Short Ratio	2.98	Perf Half Y	-55.32%
Book/sh	0.48	P/B	1.31	EPS next Y	7.54%	ROA	-76.61%	Short Interest	3.95M	Perf Year	-71.75%
Cash/sh	0.97	P/C	0.64	EPS next 5Y	-	ROE	-139.06%	52W Range	0.61 - 4.02	Perf YTD	-74.39%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-25.30%	ROI	-356.22%	52W High	-84.56%	Beta	1.07
Dividend TTM	-	Quick Ratio	3.11	Sales past 5Y	-56.91%	Gross Margin	90.32%	52W Low	1.74%	ATR (14)	0.16
Dividend Ex-Date	-	Current Ratio	3.11	EPS Y/Y TTM	35.84%	Oper. Margin	-783.95%	RSI (14)	19.63	Volatility	24.58% 11.16%
Employees	65	Debt/Eq	0.05	Sales Y/Y TTM	-	Profit Margin	-743.79%	Recom	1.50	Target Price	8.67
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	68.57%	Payout	-	Rel Volume	1.33	Prev Close	0.61
Sales Surprise	-	EPS Surprise	46.77%	Sales Q/Q	-	Earnings	Nov 07 AMC	Avg Volume	1.32M	Price	0.62
SMA20	-54.97%	SMA50	-63.26%	SMA200	-68.69%	Trades		Volume	1,757,079	Change	1.57%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-13-24	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-15-22	Initiated	JMP Securities	Mkt Outperform	$17
May-05-22	Downgrade	Credit Suisse	Outperform → Neutral	$35 → $5
Mar-21-22	Initiated	H.C. Wainwright	Buy	$25
Oct-15-21	Resumed	BTIG Research	Buy	$68
Jun-28-21	Initiated	ROTH Capital	Buy	$75
May-05-21	Resumed	Credit Suisse	Outperform	$68
Apr-26-21	Resumed	Credit Suisse	Outperform	$68
Jan-11-21	Initiated	JP Morgan	Overweight	$45
Jan-11-21	Initiated	Jefferies	Buy	$51
Jan-11-21	Initiated	Credit Suisse	Outperform	$49
Jan-11-21	Initiated	BTIG Research	Buy	$47

Show Previous Ratings

Dec-20-24 09:00AM	BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points (GlobeNewswire) -41.82%
Dec-16-24 08:00AM	BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting (GlobeNewswire) -6.90%
Dec-10-24 08:00AM	BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic and Translational Science Meeting (GlobeNewswire)
08:00AM	BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting (GlobeNewswire)
Nov-08-24 04:03PM	BioAtla Inc (BCAB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com) -5.41% +12.86%
04:01PM	Loading…
Nov-07-24 04:01PM	BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress (GlobeNewswire) +7.77%
Oct-31-24 08:00AM	BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024 (GlobeNewswire)
Oct-20-24 04:06PM	BioAtla, Inc. (BCAB): Among Michael Burry's Top 10 Stock Picks Heading Into 2025 (Insider Monkey)
Oct-09-24 05:57PM	BioAtla Inc (BCAB) Q2 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges (GuruFocus.com)
Oct-04-24 09:05AM	BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire) -6.38%
Oct-01-24 08:00AM	BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress (GlobeNewswire)
Sep-23-24 07:30AM	BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody (GlobeNewswire)
Sep-16-24 08:00AM	BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting (GlobeNewswire) -7.18%
Sep-09-24 08:00AM	BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting (GlobeNewswire)
Aug-28-24 08:00AM	BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
04:05PM	Loading…
Aug-08-24 04:05PM	Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress (GlobeNewswire) +5.76%
Aug-01-24 08:00AM	BioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024 (GlobeNewswire)
Jul-31-24 01:11PM	These 2 Strong Buy Penny Stocks Are Poised for a Big Rally, Say Analysts (TipRanks) +11.04%
Jul-25-24 05:39PM	BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day (GlobeNewswire)
Jul-24-24 12:54PM	BioAtla receives FDA fast track designation for ozuriftamab vedotin (Pharmaceutical Technology)
Jul-23-24 08:00AM	BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (GlobeNewswire)
Jun-27-24 08:00AM	BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024 (GlobeNewswire)
May-29-24 08:00AM	BioAtla to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) -9.52%
May-23-24 05:05PM	BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -7.89% -18.57%
May-15-24 08:18AM	BioAtla, Inc. (NASDAQ:BCAB) Q1 2024 Earnings Call Transcript (Insider Monkey) +14.94%
07:01AM	BioAtla Inc (BCAB) (Q1 2024) Earnings Call Transcript Highlights: Strategic Adjustments and ... (GuruFocus.com)
May-14-24 08:57PM	BCAB Stock Earnings: BioAtla Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress (GlobeNewswire)
May-08-24 08:00AM	BioAtla to Participate in the Citizens JMP Life Sciences Conference (GlobeNewswire)
May-07-24 08:00AM	BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024 (GlobeNewswire)
09:14AM	Loading…
May-06-24 09:14AM	BioAtla's Multiple Cancer Drug Candidate Receives FDA Clearance (MT Newswires)
08:00AM	BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors (GlobeNewswire)
Apr-24-24 04:35PM	BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Mar-27-24 10:07AM	BioAtla, Inc. (NASDAQ:BCAB) Q4 2023 Earnings Call Transcript (Insider Monkey) +14.95%
07:56AM	Q4 2023 Bioatla Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-26-24 09:54PM	BCAB Stock Earnings: BioAtla Beats EPS for Q4 2023 (InvestorPlace) +29.18%
05:33PM	BioAtla Inc (BCAB) Posts Q4 and Full Year 2023 Financial Results (GuruFocus.com)
04:01PM	BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress (GlobeNewswire)
Mar-19-24 08:00AM	BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024 (GlobeNewswire) +5.13%
Mar-07-24 08:00AM	BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Dec-20-23 08:00AM	BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-13-23 08:00AM	BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types (GlobeNewswire) +23.26%
Dec-06-23 08:00AM	BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023 (GlobeNewswire)
Dec-05-23 08:00AM	BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event (GlobeNewswire)
Nov-30-23 08:00AM	BioAtla to Participate in the JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-28-23 08:00AM	BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC (GlobeNewswire) +8.16%
Nov-12-23 09:24AM	BioAtla, Inc. (NASDAQ:BCAB) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 04:01PM	BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress (GlobeNewswire) -6.25%
Nov-06-23 04:05PM	BioAtla to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-12-23 07:30AM	BioAtla's Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award (GlobeNewswire) -5.46%
Oct-10-23 07:30AM	BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023 (GlobeNewswire) +15.12%
Sep-06-23 08:00AM	BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-03-23 04:01PM	BioAtla to Participate in Upcoming Investor Conferences in August (GlobeNewswire) -8.67%
06:48AM	BioAtla, Inc. (NASDAQ:BCAB) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-02-23 11:31AM	Q2 2023 Bioatla Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-01-23 04:01PM	BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress (GlobeNewswire)
Jul-25-23 08:00AM	BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023 (GlobeNewswire)
Jul-07-23 07:09AM	With 51% ownership of the shares, BioAtla, Inc. (NASDAQ:BCAB) is heavily dominated by institutional owners (Simply Wall St.)
Jun-26-23 08:00AM	BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index (GlobeNewswire) -9.43%
May-31-23 08:00AM	BioAtla to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-11-23 04:01PM	BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress (GlobeNewswire) +14.33%
May-08-23 04:05PM	BioAtla to Participate in the JMP Securities Life Sciences Conference (GlobeNewswire) -9.44%
May-04-23 08:00AM	BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023 (GlobeNewswire)
Apr-29-23 09:29AM	We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully (Simply Wall St.)
Mar-31-23 06:36AM	Daily Vickers Top Buyers & Sellers for 03/31/2023 (Argus Research) +8.94%
Mar-27-23 07:12AM	BioAtla, Inc. (NASDAQ:BCAB) Q4 2022 Earnings Call Transcript (Insider Monkey) +5.51%
Mar-24-23 11:31AM	Q4 2022 Bioatla Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-23-23 04:05PM	BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress (GlobeNewswire)
Mar-16-23 08:00AM	BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights (GlobeNewswire)
Feb-27-23 08:07AM	BioAtla Announces Change in Executive Leadership (GlobeNewswire)
Feb-23-23 08:00AM	BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma (GlobeNewswire) -8.83%
Jan-25-23 07:10AM	Recent uptick might appease BioAtla, Inc. (NASDAQ:BCAB) institutional owners after losing 56% over the past year (Simply Wall St.) -5.39%
Jan-10-23 08:00AM	BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones (GlobeNewswire) -46.24%
Dec-29-22 04:05PM	Viatris Announces Appointments of Scott A. Smith and Elisha W. Finney to the Company's Board of Directors (PR Newswire)
Dec-22-22 08:00AM	BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-08-22 08:54AM	BioAtla, Inc.'s stock is down 11%, but insiders still have about US$393k in profit after buying earlier this year (Simply Wall St.)
Dec-01-22 09:55AM	Does BioAtla, Inc. (BCAB) Have the Potential to Rally 114% as Wall Street Analysts Expect? (Zacks)
Nov-15-22 09:55AM	Can BioAtla, Inc. (BCAB) Climb 260% to Reach the Level Wall Street Analysts Expect? (Zacks) -7.47%
Nov-11-22 08:38AM	Companies Like BioAtla (NASDAQ:BCAB) Are In A Position To Invest In Growth (Simply Wall St.) +10.32%
Nov-08-22 08:00AM	BioAtla to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-04-22 11:15AM	BioAtla, Inc. (BCAB) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +18.71%
09:08AM	BioAtla Announces $65 Million Underwritten Offering of its Common Stock (GlobeNewswire)
Nov-03-22 04:01PM	BioAtla Reports Third Quarter 2022 Financial Results and Highlights Recent Progress (GlobeNewswire)
Oct-27-22 08:00AM	BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022 (GlobeNewswire)
Sep-23-22 09:15AM	Australian Billionaire Kerr Neilson is Selling These 15 Stocks (Insider Monkey) -5.76%
Sep-21-22 10:14AM	J.P. Morgan Says Stock Market Downside Risk Is Limited; Here Are 3 Stocks to Consider (TipRanks)
Sep-12-22 10:08AM	Himalaya Therapeutics Announces Interim Phase 2 Results for Mecbotamab vedotin (HTBA3011) (PR Newswire) -7.12%
Aug-18-22 06:39AM	Do Insiders Own Lots Of Shares In BioAtla, Inc. (NASDAQ:BCAB)? (Simply Wall St.)
Aug-09-22 07:25PM	BioAtla, Inc. (BCAB) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +83.10%
04:05PM	BioAtla Reports Second Quarter 2022 Financial Results And Highlights Recent Progress (GlobeNewswire)
Aug-03-22 08:00AM	BioAtla to Participate in the 2022 BTIG Biotechnology Conference (GlobeNewswire) +5.81%
Aug-02-22 08:00AM	BioAtla to Announce Second Quarter 2022 Financial Results and Provide Business Highlights on August 9, 2022 (GlobeNewswire) +5.20%
Jun-04-22 08:12AM	Here's Why We're Watching BioAtla's (NASDAQ:BCAB) Cash Burn Situation (Simply Wall St.)
Jun-01-22 04:05PM	BioAtla to Participate in 2022 Jefferies Global Healthcare Conference (GlobeNewswire)
May-04-22 04:01PM	BioAtla Reports First Quarter 2022 Financial Results and Highlights Recent Progress (GlobeNewswire) +6.53% -41.18%
Apr-08-22 08:00AM	BioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022 (GlobeNewswire)
Mar-01-22 06:00AM	BIOATLA ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS (PR Newswire)
Feb-07-22 05:38PM	Monashee Investment Management LLC Buys Vanguard Total Stock Market ETF, Hyperfine Inc, Agree ... (GuruFocus.com) -6.53%
Jan-10-22 04:05PM	BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (nivolumab) for Treatment of Solid Tumors (PR Newswire) -7.10%
Dec-21-21 09:00AM	BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF DIRECTORS (PR Newswire)

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BCAB

BioAtla Inc

Upgrade your FINVIZ experience